United Therapeutics had its Relative Strength (RS) Rating upgraded from 78 to 81 Wednesday.
IBD's unique rating measures price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the top-performing stocks typically have an RS Rating north of 80 in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
United Therapeutics is not currently showing a potential buy point. See if the stock goes on to build a sound pattern that could kick off a new climb.
The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 12% to 19%. Revenue rose from 20% to 23%. The company is expected to report its latest results on or around Feb. 19.
The company holds the No. 5 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals is the No. 1-ranked stock within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
